Silo Pharma Inks Agreement To Develop First-in-Class Ketamine Implant Therapeutic
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has signed an agreement to develop a first-in-class ketamine implant therapeutic, which includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
June 13, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's agreement to develop a first-in-class ketamine implant therapeutic could potentially boost its stock price in the short term.
The agreement to develop a first-in-class ketamine implant therapeutic is a significant milestone for Silo Pharma. This development could potentially lead to a new revenue stream and increased investor interest, which may positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100